STE vs. EW, ALGN, ZBH, SNN, MOH, BAX, ILMN, BNTX, WAT, and GMAB
Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), Smith & Nephew (SNN), Molina Healthcare (MOH), Baxter International (BAX), Illumina (ILMN), BioNTech (BNTX), Waters (WAT), and Genmab A/S (GMAB). These companies are all part of the "medical" sector.
STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking.
STERIS currently has a consensus price target of $239.60, indicating a potential upside of 16.15%. Edwards Lifesciences has a consensus price target of $92.71, indicating a potential upside of 9.00%. Given STERIS's higher possible upside, equities analysts plainly believe STERIS is more favorable than Edwards Lifesciences.
Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Edwards Lifesciences has a net margin of 23.01% compared to STERIS's net margin of 10.48%. Edwards Lifesciences' return on equity of 22.86% beat STERIS's return on equity.
94.7% of STERIS shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 1.0% of STERIS shares are held by company insiders. Comparatively, 1.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Edwards Lifesciences received 987 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 71.79% of users gave Edwards Lifesciences an outperform vote while only 58.68% of users gave STERIS an outperform vote.
In the previous week, Edwards Lifesciences had 26 more articles in the media than STERIS. MarketBeat recorded 40 mentions for Edwards Lifesciences and 14 mentions for STERIS. Edwards Lifesciences' average media sentiment score of 0.59 beat STERIS's score of 0.49 indicating that Edwards Lifesciences is being referred to more favorably in the news media.
STERIS has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Summary
Edwards Lifesciences beats STERIS on 15 of the 18 factors compared between the two stocks.
Get STERIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
